U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Aggressive Non-Hodgkin Lymphoma

MedGen UID:
1657821
•Concept ID:
C4744674
•
Neoplastic Process

Definition

An aggressive non-Hodgkin lymphoma that is resistant to treatment. [from NCI]

Professional guidelines

PubMed

Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma.
Whittington MD, McQueen RB, Ollendorf DA, Kumar VM, Chapman RH, Tice JA, Pearson SD, Campbell JD
JAMA Netw Open 2019 Feb 1;2(2):e190035. doi: 10.1001/jamanetworkopen.2019.0035. PMID: 30794298Free PMC Article
Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.
Mukherji D, Pettengell R
Expert Opin Pharmacother 2010 Aug;11(11):1915-23. doi: 10.1517/14656566.2010.494180. PMID: 20569087

Recent clinical studies

Etiology

A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score.
Yhim HY, Eshet Y, Metser U, Lim CH, Lajkosz K, Isaev K, Cooper M, Prica A, Kukreti V, Bhella S, Lang N, Lee KH, Xu W, Hodgson D, Tsang R, Yoon SE, Kim SJ, Kim WS, Crump M, Kuruvilla J, Kridel R
Blood Adv 2020 Nov 24;4(22):5762-5771. doi: 10.1182/bloodadvances.2020002814. PMID: 33216888Free PMC Article
Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M, Hus I, Puła B, Jurczyszyn A, Chojnacki T, Blajer-Olszewska B, Drozd-Sokołowska J, Raźny M, Romejko-Jarosińska J, Taszner M, Jurczak W
Pharmacol Rep 2019 Jun;71(3):473-477. Epub 2019 Feb 6 doi: 10.1016/j.pharep.2019.02.001. PMID: 31003160
Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.
Pettengell R, Coiffier B, Egorov A, Singer J, Sivcheva L
Clin Drug Investig 2018 Jun;38(6):527-533. doi: 10.1007/s40261-018-0635-3. PMID: 29564722Free PMC Article
Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial.
Jo JC, Baek JH, Lee JH, Joo YD, Bae SH, Lee JL, Lee JH, Kim DY, Lee WS, Ryoo HM, Choi Y, Kim H, Lee KH; CoOperative Study Group A for Hematology (COSAH)
Asia Pac J Clin Oncol 2016 Jun;12(2):159-66. Epub 2016 Mar 9 doi: 10.1111/ajco.12462. PMID: 26956432
Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma.
Tseng YD, Chen YH, Catalano PJ, Ng A
Int J Radiat Oncol Biol Phys 2015 Jan 1;91(1):223-31. doi: 10.1016/j.ijrobp.2014.09.041. PMID: 25835625

Diagnosis

Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.
Pettengell R, Coiffier B, Egorov A, Singer J, Sivcheva L
Clin Drug Investig 2018 Jun;38(6):527-533. doi: 10.1007/s40261-018-0635-3. PMID: 29564722Free PMC Article
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.
Witzig TE, Tomblyn MB, Misleh JG, Kio EA, Sharkey RM, Wegener WA, Goldenberg DM
Haematologica 2014 Nov;99(11):1738-45. Epub 2014 Aug 22 doi: 10.3324/haematol.2014.112110. PMID: 25150258Free PMC Article
High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphoma.
Vijay A, Duan Q, Henning JW, Duggan P, Daly A, Shafey M, Bahlis NJ, Stewart DA
Leuk Lymphoma 2013 Dec;54(12):2620-6. Epub 2013 Apr 16 doi: 10.3109/10428194.2013.783211. PMID: 23472969

Therapy

Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma.
Zlotnick M, Avigdor A, Ribakovsky E, Nagler A, Kedmi M
Acta Haematol 2019;141(2):84-90. Epub 2019 Jan 10 doi: 10.1159/000495283. PMID: 30630175
Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.
Belada D, Georgiev P, Dakhil S, Inhorn LF, Andorsky D, Beck JT, Quick D, Pettengell R, Daly R, Dean JP, Pavlyuk M, Failloux N, Hübel K
Future Oncol 2016 Aug;12(15):1759-68. Epub 2016 Apr 20 doi: 10.2217/fon-2016-0137. PMID: 27093976
Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma.
Tseng YD, Chen YH, Catalano PJ, Ng A
Int J Radiat Oncol Biol Phys 2015 Jan 1;91(1):223-31. doi: 10.1016/j.ijrobp.2014.09.041. PMID: 25835625
Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
Kruger PC, Cooney JP, Turner JH
Cancer Biother Radiopharm 2012 Nov;27(9):552-60. Epub 2012 Oct 12 doi: 10.1089/cbr.2012.1275. PMID: 23062193
Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.
Mukherji D, Pettengell R
Expert Opin Pharmacother 2010 Aug;11(11):1915-23. doi: 10.1517/14656566.2010.494180. PMID: 20569087

Prognosis

A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score.
Yhim HY, Eshet Y, Metser U, Lim CH, Lajkosz K, Isaev K, Cooper M, Prica A, Kukreti V, Bhella S, Lang N, Lee KH, Xu W, Hodgson D, Tsang R, Yoon SE, Kim SJ, Kim WS, Crump M, Kuruvilla J, Kridel R
Blood Adv 2020 Nov 24;4(22):5762-5771. doi: 10.1182/bloodadvances.2020002814. PMID: 33216888Free PMC Article
Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma.
Zlotnick M, Avigdor A, Ribakovsky E, Nagler A, Kedmi M
Acta Haematol 2019;141(2):84-90. Epub 2019 Jan 10 doi: 10.1159/000495283. PMID: 30630175
An interim analysis of the ZUMA-1 study of KTE-C19 in refractory, aggressive non-Hodgkin lymphoma.
Neelapu SS
Clin Adv Hematol Oncol 2017 Feb;15(2):117-120. PMID: 28398281
Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma.
Tseng YD, Chen YH, Catalano PJ, Ng A
Int J Radiat Oncol Biol Phys 2015 Jan 1;91(1):223-31. doi: 10.1016/j.ijrobp.2014.09.041. PMID: 25835625
Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE.
Aurer I, Mitrović Z, Nemet D, Radman I, Sertić D, Serventi-Seiwerth R, Stern-Padovan R, Santek F, Nola M, Mrsić M, Labar B
J Chemother 2008 Oct;20(5):640-4. doi: 10.1179/joc.2008.20.5.640. PMID: 19048695

Clinical prediction guides

A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score.
Yhim HY, Eshet Y, Metser U, Lim CH, Lajkosz K, Isaev K, Cooper M, Prica A, Kukreti V, Bhella S, Lang N, Lee KH, Xu W, Hodgson D, Tsang R, Yoon SE, Kim SJ, Kim WS, Crump M, Kuruvilla J, Kridel R
Blood Adv 2020 Nov 24;4(22):5762-5771. doi: 10.1182/bloodadvances.2020002814. PMID: 33216888Free PMC Article
Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M, Hus I, Puła B, Jurczyszyn A, Chojnacki T, Blajer-Olszewska B, Drozd-Sokołowska J, Raźny M, Romejko-Jarosińska J, Taszner M, Jurczak W
Pharmacol Rep 2019 Jun;71(3):473-477. Epub 2019 Feb 6 doi: 10.1016/j.pharep.2019.02.001. PMID: 31003160
Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma.
Zlotnick M, Avigdor A, Ribakovsky E, Nagler A, Kedmi M
Acta Haematol 2019;141(2):84-90. Epub 2019 Jan 10 doi: 10.1159/000495283. PMID: 30630175
Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.
Pettengell R, Coiffier B, Egorov A, Singer J, Sivcheva L
Clin Drug Investig 2018 Jun;38(6):527-533. doi: 10.1007/s40261-018-0635-3. PMID: 29564722Free PMC Article
Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma.
Tseng YD, Chen YH, Catalano PJ, Ng A
Int J Radiat Oncol Biol Phys 2015 Jan 1;91(1):223-31. doi: 10.1016/j.ijrobp.2014.09.041. PMID: 25835625

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...